# Genus plc (GNS.L) fundamentals

Data as of 2026-09-08. LSE, United Kingdom. Sector: Healthcare / Biotechnology. Price 2310p, market value 1.5 billionp.

## Valuation
- **P/E (trailing): 32.5×** (5-yr avg 7210.9×, 3-yr avg 8375.6×). Genus plc trades at 32.5× trailing earnings, well below its own five-year average of 7210.9×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 22.1×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.16**. A PEG of 0.16 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.1×**. Each dollar of revenue is priced at 1.1×.
- **Price / book: 3.0×**. The shares trade at 3.0× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 11.1×**. Enterprise value is 11.1× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 6.2%** (5-yr avg 0.0%). Free cash flow equals 6.2% of the market value, above its five-year average of 0.0%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 3.1%**. The inverse of the P/E: 3.1% of the price is earned each year.

## Profitability
- **Gross margin: 98.4%**. Genus plc keeps 98.4% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 4.7%**. 4.7% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 2.9%**. 2.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 4.1%**. 4.1% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 5.5%**. Return on all capital, debt included, is 5.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 4.8%**. Each dollar of assets produces 4.8% of profit.

## Growth
- **Revenue growth (1 yr): 0.6%** (3-yr 4.3%/yr, 5-yr 4.1%/yr). Revenue grew 0.6% over the last year, against 4.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 141.7%** (3-yr -22.4%/yr, 5-yr -11.7%/yr). Earnings per share rose 141.7%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.56**. Debt is 0.56 times equity, moderate leverage.
- **Net debt / EBITDA: 1.4×**. It would take 1.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 1.5×**. Operating profit covers interest 1.5×, thin but manageable.
- **Current ratio: 1.94** (quick 1.32). Current assets cover the next year's liabilities 1.94 times.
- **Altman Z-score: 3.96**. A Z-score of 3.96 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 1.45%** (0p per share, trailing). Genus plc yields 1.45%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 109%** (44% of free cash flow). The dividend exceeds earnings (109% payout), though free cash flow still covers it.
- **Consecutive years of increases: 11**. 11 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 1.9%/yr** (1-yr 0.0%). The dividend has grown 1.9% a year over five years.
- **Shareholder yield: 1.4%**. Dividends plus net buybacks return 1.4% of the market value a year.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Genus plc; the consensus is strong_buy, with an average price target of 3062p (+33% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -15.8%** (YTD -12.8%, 3-mo 1.2%). The shares are down 15.8% over twelve months including dividends.
- **From 52-week high: -28.3%** (18.9% above the low). Trading 28% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 48**. An RSI of 48 is neutral.
- **Beta (1 yr): 1.02** (volatility 36%). Beta of 1.02 against the FTSE All-Share: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GNS.L · Page: https://foliofundamentals.com/stocks/gns.l

Not investment advice.